Loss of cBAF Complex Confers Sorafenib Resistance in Liver Cancer
Jacqueline A. BrinkmaniD, Margarita M. DzamaiD, Max BucklaniD, Carl J. ManneriD, Mallory SokolowskiiD, Jesse R. RaabiD
Abstract
Sorafenib resistance limits the clinical benefit of first-line therapy in hepatocellular carcinoma (HCC), yet the epigenetic mechanisms underlying this resistance remain poorly understood. Using a chromatin-focused CRISPR/Cas9 dropout screen in HepG2 cells, we identified subunits of the canonical BAF (cBAF) complex -- ARID1A, ARID1B, and SMARCC1 -- as functional drivers of sorafenib resistance, while loss of the PBAF-specific subunit ARID2 had no effect, implicating cBAF specifically rather than SWI/SNF broadly. ARID1A and ARID1B mutations are associated with significantly worse overall survival in TCGA hepatocellular carcinoma cohorts. To define the underlying mechanism, we performed CUT&RUN profiling and RNA-seq in ARID1B-knockout HepG2 cells under sorafenib treatment. ARID1B loss triggered selective depletion of H3K4me3 and H3K27ac at 74 cBAF-dependent regulatory elements, 72% of which were directly occupied by ARID1B in wild-type cells. These sites were enriched for FOXA1 and HNF4 motifs, consistent with disruption of hepatocyte lineage regulatory chromatin. Direct profiling in HLF hepatocellular carcinoma cells confirmed that 179 FOXA1 binding sites were lost specifically under the combined perturbation of ARID1B loss and sorafenib treatment, with neither condition alone sufficient to drive this effect. Transcriptionally, ARID1B loss induced epithelial-mesenchymal transition programs and suppressed MYC targets, E2F targets, and mTORC1 signaling. These findings define a cBAF-FOXA1 regulatory axis that maintains hepatocyte lineage identity under kinase inhibitor stress, and whose disruption drives epigenetic reprogramming toward a mesenchymal drug-tolerant state. Graphical Abstract O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=92 SRC="FIGDIR/small/731725v1_ufig1.gif" ALT="Figure 1"> View larger version (18K): org.highwire.dtl.DTLVardef@1ce2352org.highwire.dtl.DTLVardef@70f2f5org.highwire.dtl.DTLVardef@15ee96borg.highwire.dtl.DTLVardef@2e7edd_HPS_FORMAT_FIGEXP M_FIG C_FIG
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 0
- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- In vivo screen identifies LXR agonism potentiates sorafenib killing of hepatocellular carcinoma
M. E. Preziosi, A. M. Zahm, … K. J. Wangensteen·bioRxiv·Jun 13, 2019
- Loss-of-SIRT7 sensitizes hepatocellular carcinoma to sorafenib through the regulation of ERK Phosphorylation
Y. Kim, K.-Y. Jung, … J. Auwerx·bioRxiv·Mar 13, 2023
- CCT3 drives Sorafenib resistance by inhibiting TFRC-mediated iron uptake in HCC
Huihui Zhu, Qiuhong Liu, … Feiyang Ji·Journal of Experimental & Clinical Cancer ResearchPeer-reviewed·Aug 29, 2024
- Fasting reverses drug-resistance in hepatocellular carcinoma through p53-dependent metabolic synergism
J. Krstic, I. Reinisch, … A. Prokesch·bioRxiv·Feb 10, 2021
- Genomic analyses identify key molecules and significant signaling pathways in Sorafenib treated hepatocellular cancer cells
Tingxiang Chang, Mengshan Wang·bioRxiv·Mar 15, 2022
- SYNERGISTIC ANTITUMOR EFFECT OF NAPROXEN AND SORAFENIB IN HEPATOCELLULAR CARCINOMA
Etkin Akar, Şeyma Ünsal Beyge, Deniz Cansen Kahraman·bioRxiv·Feb 1, 2024